Last reviewed · How we verify
Mozobil
At a glance
| Generic name | Mozobil |
|---|---|
| Also known as | Plerixafor, AMD 3100, AMD3100, plerixafor |
| Sponsor | University of Washington |
| Target | Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant lymphoma
- Multiple myeloma
- Peripheral Mobilization of Hematopoietic Stem Cells
- Solid malignant tumours
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Injection site reactions
- Headache
- Arthralgia
- Dizziness
- Vomiting
- Hyperleukocytosis
- Abdominal pain
- Hyperhidrosis
- Abdominal distention
Serious adverse events
- Allergic reactions
- Vasovagal reactions
- Orthostatic hypotension
- Syncope
- Dyspnea
- Hypoxia
- Periorbital swelling
- Urticaria
Key clinical trials
- A Phase I Study of Mozobil in the Treatment of Patients With WHIMS (PHASE1, PHASE2)
- Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models (PHASE2)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia (PHASE1, PHASE2)
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (PHASE1, PHASE2)
- CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors (NA)
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (PHASE2)
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mozobil CI brief — competitive landscape report
- Mozobil updates RSS · CI watch RSS
- University of Washington portfolio CI